Patents by Inventor Ana Ortega Molina

Ana Ortega Molina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DIAGNOSING AND TREATING FOLLICULAR LYMPHOMA
    Publication number: 20180223368
    Abstract: The invention relates generally to methods for diagnosis and treatment of follicular lymphoma or diffuse large B cell lymphoma. Specifically, the invention relates to detecting a lysine (K)-specific methyltransferase 2D (KMT2D) alteration to diagnose or treat follicular lymphoma or diffuse large B cell lymphoma.
    Type: Application
    Filed: March 17, 2016
    Publication date: August 9, 2018
    Applicants: Memorial Sloan Ketteting Cancer Center, CORNELL UNIVERSITY
    Inventors: Hans-Guido WENDEL, Ari MELNICK, Ana ORTEGA MOLINA, Isaac BOSS
  • Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing
    Patent number: 9993554
    Abstract: The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-? (Pgd1?) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: June 12, 2018
    Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)
    Inventors: Manuel Serrano Marugan, Joaquin Pastor Fernández, Sonia Martínez González, Ana Ortega Molina, James R. Bischoff, Julen Oyarzabal Santamarina
  • Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing
    Publication number: 20140154232
    Abstract: The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-? (Pgd1?) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.
    Type: Application
    Filed: June 1, 2011
    Publication date: June 5, 2014
    Applicant: Centro Nacional De Investigaciones Oncologicas (CNIO)
    Inventors: Manuel Serrano Marugan, Joaquin Pastor Fernández, Sonia Martínez González, Ana Ortega Molina, James R. Bischoff, Julen Oyarzabal Santamarina